Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Asch

Showing results (111-120 of 121) with videos related to

Pageof 13
Sort By:
BMC Cancer|May 8, 2019
A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancerConstantin Georgescu, Joshua M Corbin, Sandra Thibivilliers, et al.
Health Services Research|June 17, 2000
Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV Cost and Services Utilization StudyR Andersen, S Bozzette, M Shapiro, et al.
Bone Marrow Transplantation|April 12, 2022
Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care centerAzra Borogovac, Amany Keruakous, Michelle Bycko, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 8, 2023
Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic MalignanciesManish R Patel, William Donnellan, Michael Byrne, et al.
British Journal of Haematology|July 23, 2016
A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphomaSteven I Park, Natalie S Grover, Oludamilola Olajide, et al.
Ejhaem|May 14, 2025
Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Acute Myeloid LeukaemiaGabriel N Mannis, Camille N Abboud, Naval G Daver, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2023
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib ResultsNaval G Daver, Paresh Vyas, Suman Kambhampati, et al.
Leukemia & Lymphoma|December 15, 2022
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612Sarit Assouline, Laura C Michaelis, Megan Othus, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 8, 2025
Induction of immune tolerance in living related human leukocyte antigen-matched kidney transplantation: A phase 3 randomized clinical trialDixon B Kaufman, Sanjeev K Akkina, Mark D Stegall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2023
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib StudyDavid A Sallman, Monzr M Al Malki, Adam S Asch, et al.
Pageof 13

Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
BMC Cancer|May 8, 2019
A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancerConstantin Georgescu, Joshua M Corbin, Sandra Thibivilliers, et al.
Health Services Research|June 17, 2000
Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV Cost and Services Utilization StudyR Andersen, S Bozzette, M Shapiro, et al.
Bone Marrow Transplantation|April 12, 2022
Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care centerAzra Borogovac, Amany Keruakous, Michelle Bycko, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 8, 2023
Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic MalignanciesManish R Patel, William Donnellan, Michael Byrne, et al.
British Journal of Haematology|July 23, 2016
A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphomaSteven I Park, Natalie S Grover, Oludamilola Olajide, et al.
Ejhaem|May 14, 2025
Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Acute Myeloid LeukaemiaGabriel N Mannis, Camille N Abboud, Naval G Daver, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2023
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib ResultsNaval G Daver, Paresh Vyas, Suman Kambhampati, et al.
Leukemia & Lymphoma|December 15, 2022
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612Sarit Assouline, Laura C Michaelis, Megan Othus, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 8, 2025
Induction of immune tolerance in living related human leukocyte antigen-matched kidney transplantation: A phase 3 randomized clinical trialDixon B Kaufman, Sanjeev K Akkina, Mark D Stegall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2023
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib StudyDavid A Sallman, Monzr M Al Malki, Adam S Asch, et al.
Pageof 13